Description: Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. The company operates through two segments, Drug Development and Chromatography. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA HPLC analytical columns. The company provides products for the analysis and purification of substances, with a focus on peptides and diabetes drugs. In addition, it is involved in the development of nanoporous amorphous particles (NAP), a platform technology for inhalation to give access to new or enhanced treatments for the patients with severe lung diseases. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Home Page: www.nanologica.com
Forskargatan 20 G
Södertälje,
151 36
Sweden
Phone:
46 8 41 07 49 49
Officers
| Name | Title |
|---|---|
| Mr. Andreas Bhagwani | Chief Executive Officer |
| Ms. Eva Osterman | Chief Financial Officer |
| Ms. Åsa Bergström | Chief Operating Officer |
| Johanna Johansson | Director of IR, Communications & Marketing |
| Dr. P. K. Dutta | Senior VP of Sales & Senior Advisor of Chromatography |
| Ms. Katarina Alenas | Senior Vice President of Chromatography |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.4906 |
| Price-to-Sales TTM: | 1.6245 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |